Medication adherence is usually treated as a patient-behavior problem, and that framing costs independent practices real ground. The national data says the prescription most often fails before the patient ever gets a chance to take a pill wrong. The IQVIA Institute’s U.S. Medicine Use Trends 2026, published April 28, 2026, puts the unfilled rate across all brands at 29%. For novel medicines launched between 2020 and 2024 it is far worse: only 35% of those prescriptions were filled, and 65% went unfilled. IQVIA attributes that unfilled volume to 49% rejected by payers and 17% abandoned by patients after the payer had already approved the claim, the latter likely on out-of-pocket cost. Very little of it is forgetfulness.
So the practical medication adherence question for a practice is narrower than “how do we make patients more compliant.” It is: which failure points sit inside your four walls, and which do not. Three of them do. You can see the patient’s actual out-of-pocket cost before they leave, you can hand them the first fill in the office instead of sending them to a counter, and you can make the follow-up conversation happen at a visit you already have scheduled. This article walks the failure points in order, shows what the published numbers actually say, and covers what a practice has to check before it starts dispensing in-office.
What does medication adherence actually measure?
Two different things get bundled under the medication adherence label, and separating them changes what you do about it.
Primary non-adherence is the prescription that is written and never filled at all. The clinical literature defines it precisely. Li and colleagues, writing in Exploratory Research in Clinical and Social Pharmacy (2024;15:100484), used the definition of a prescription order sent to the pharmacy electronically, by telephone, or by fax that is never picked up by the patient. Their study of community pharmacies in the Mississippi Delta measured pickup-stage abandonment at 5.44% in medically underserved areas versus 4.77% elsewhere. Note how small that is relative to the 29% all-brands figure above. Most unfilled prescriptions are lost upstream of the pharmacy counter, at the payer.
Secondary non-adherence is the patient who fills the first prescription and then stops, skips doses, or stretches the supply. This is the part most medication adherence programs are built around, and it is the part a practice sees at the follow-up visit rather than at the point of prescribing.
The distinction matters because the interventions are unrelated. Refill reminders do nothing for a prescription that was rejected at adjudication. A benefit check does nothing for a patient who quit at week six because of side effects. A practice that measures only one of the two will keep spending effort in the wrong place.
Why do patients not fill the prescription?
Two causes dominate, and only one of them is about the patient. IQVIA separates the unfilled volume into prescriptions rejected by payers and prescriptions abandoned after the payer already approved them, and it is explicit that the second group is walking away over out-of-pocket cost rather than over intent. The cost pressure behind that is measurable: the same report puts patient out-of-pocket spending at $110 billion in 2025, up $6 billion year over year, with commercial-plan out-of-pocket costs rising 5% in 2025 and 37% over five years.
The picture does not improve with time, either. IQVIA reports that for those novel medicines, by year four more than half of new prescriptions still go unfilled. A practice that assumes an unfilled prescription will sort itself out at the next refill cycle is assuming something the data does not support, and the gap is widest exactly where the therapy is newest and the coverage least settled.
Put the payer split and the pickup study side by side and the shape of the problem is clear. The largest share of the loss is a coverage decision your practice can anticipate but not overrule. A meaningful second slice is a patient who was approved and still walked away, almost always over price. Only the remainder is the behavior pattern that adherence counseling is designed to address.
Where does the prescription actually break down?
It helps to lay the medication adherence path out as a sequence of gates, because each one has a different owner.
- Adjudication. The claim is submitted and the plan rejects it, asks for a prior authorization, or steps the patient to a different agent. Nothing about the patient’s intent is involved yet.
- Price disclosure. The patient learns the real number, usually at a pharmacy counter, often days after the visit and with no clinician present to discuss an alternative.
- Pickup. The fill is ready and the patient does not come to collect it. This is the narrow band the Delta-region study measured.
- Persistence. The patient starts and then stops, which is where refill gaps, side effects, and regimen complexity live.
Gates one and two both resolve while the patient is still with you, if you can see them in time. That is the entire practical case for moving parts of the medication adherence workflow into the office.
What medication adherence tools belong in an independent practice?
Four levers are realistically available to a small or mid-sized practice, and they map onto the gates above rather than onto a generic engagement strategy.
Real-time benefit checking. Running coverage while the patient is in the room turns a surprise at the counter into a two-minute conversation about a covered alternative. This addresses gate one and, indirectly, gate two.
In-office dispensing. Handing the patient the medication before they leave removes the pickup gate entirely. It does not remove the payer gate, which is a point worth being honest about internally when you are building the business case.
Formulary management. Keeping the dispensed list aligned to what your actual payer mix covers is what prevents an in-office program from simply relocating the rejection to your own shelf.
Structured follow-up. Persistence is a visit-cadence problem more than a technology problem. A short, scheduled check on tolerance and refill status catches the week-six dropout that no dispensing workflow will, and it is the only one of the four medication adherence levers that reaches the persistence gate at all.
HealthWright Technologies supports the dispensing piece through the SCRIPT physician dispensing program, which checks insurance in real time, manages the formulary, and simplifies the credentialing and billing side of running medication out of the office. It sits alongside the practice’s existing systems rather than replacing them.
Does in-office dispensing improve medication adherence?
It removes a specific failure point. That is a narrower and more defensible claim than the one usually made for it, and practices evaluating the model should hold vendors to the narrower version.
Dispensing in the office eliminates the trip to the pharmacy, so the pickup gate stops existing for those prescriptions. It also moves price disclosure forward, into a room where a clinician can still change the plan. What it does not do is override a payer rejection. Given that payer rejection is the largest single component of the unfilled volume in the IQVIA novel-medicine analysis, a practice that expects dispensing alone to close the medication adherence gap will be disappointed by its own numbers.
The realistic medication adherence framing is that in-office dispensing converts the part of the loss that is logistical, and real-time benefit checking converts part of what is financial. Both together still leave the coverage decision where it was.
What are practices actually searching for?
One useful and rarely published input here is our own search data. HealthWright’s Search Console record for the 90 days ending August 25, 2026 shows what practice staff type when they go looking for this, and the questions are more operational than the marketing category suggests.
The compound questions are the tell. People search for whether a platform supports both in-office dispensing and ship-to-patient orders in the same workflow, whether dispensing platforms are workable at small-practice scale, and how inventory is handled. Medication adherence queries such as “script adherence tools” and “script adherence monitoring software” show up in the same window with meaningful impression volume and, notably, no clicks going anywhere useful. Nobody has written the plain answer, so searchers keep bouncing.
The practical read for a practice manager evaluating this: inventory handling, small-practice viability, and whether one system covers both dispensing paths are the three questions to put to any vendor first, because they are the three that other practices are already struggling to get answered.
What has to be checked before a practice starts dispensing?
Physician dispensing is governed by state law, and the rules vary considerably. Some states permit it broadly, some restrict it by quantity or setting, and some require separate registration with the board of pharmacy or the medical board. Verify your own state’s current requirements with the relevant board before committing to a workflow, because this is the item most likely to stop a program after the equipment is already in the building.
Beyond the licensing question, four operational items decide whether a program holds up: who owns inventory and expiry tracking, how controlled substances are handled or excluded, how the dispensed medication is documented in the chart, and how the billing path is set up. None of these are exotic, but each one is a place where an under-planned program stalls in month three.
It is also worth sizing the effort honestly against your other ancillary options. Dispensing is one of several routes practices use to add clinical capability without adding visit volume, and it competes for the same staff attention as the others. Our overview of ancillary revenue for medical practices lays out how the common options compare, and the rules for DME dispensing in the physician office cover a closely related workflow with its own documentation requirements.
Frequently asked questions about medication adherence
What percentage of prescriptions are never filled?
The IQVIA Institute’s U.S. Medicine Use Trends 2026 report, published April 28, 2026, gives an unfilled rate of 29% across all brands. For novel medicines launched between 2020 and 2024 the rate is 65%, and more than half of those prescriptions are still unfilled by year four.
Is cost really the main driver of medication adherence failure?
Cost is the strongest patient-side driver, but payer rejection is larger overall. IQVIA attributes the unfilled volume for novel medicines to 49% payer rejection and 17% patient abandonment after the payer had already approved the claim. That second group is the one cost reaches, and the pressure is real: patient out-of-pocket spending hit $110 billion in 2025, with commercial-plan out-of-pocket costs up 37% over five years.
What is the difference between primary and secondary non-adherence?
Primary non-adherence means the prescription is written and never filled. Secondary non-adherence means the patient fills it and then stops, skips, or stretches doses. They have different causes and different fixes, so a practice measuring medication adherence should track the two separately rather than reporting one blended number.
Can a physician practice legally dispense medication in the office?
It depends on the state. Physician dispensing is regulated at the state level, and requirements range from open permission to registration with the board of pharmacy or the medical board, with additional restrictions on controlled substances. Confirm the current rules with your own state board before building the workflow.
Does in-office dispensing fix payer rejections?
No. Dispensing in the office removes the pharmacy pickup step and moves the cost conversation earlier, but the coverage decision still belongs to the plan. Real-time benefit checking is the tool that surfaces a rejection while the patient is still in the room, which is what allows a covered alternative to be selected on the spot.
Working the medication adherence problem where you can actually reach it
The useful medication adherence conclusion from the published numbers is not that patients need more reminding. It is that a large share of the loss happens in the days between the visit and the pharmacy counter, in a window where the practice has no visibility and no ability to intervene. Closing that window is an operational change, and it is available to independent practices without adding new visit types.
HealthWright Technologies has worked with independent physicians since 2000, supplying in-office capability along with training, implementation, and ongoing support. You can review the full lineup on our products page or see how the pieces fit a specific practice model under solutions for your practice. To talk through whether in-office dispensing fits your payer mix and state rules, contact our team at contact@healthwrighttechnologies.com or call (678) 322-7146. HealthWright Technologies, 60 Bear Creek Marina Rd, Mansfield, GA 30055.
This article is general educational information for healthcare professionals and is not medical, legal, or billing advice. Consult your healthcare provider before starting any new treatment. Verify dispensing requirements with your state licensing board and confirm coverage rules with the applicable payer.
Ready to see the CMAT Advantage in your practice?
Book a free 25-minute demo: see the full PAD + autonomic workup and how the three established CPT codes apply, with no obligation. Backed by our 90-day buyback guarantee.
Book a Free Demo →
